24/7 Wall Street
21 Nov 2026, 17:35 UTC · 41m ago
Abbott Has Lost More Than 10% This Year, and $1,000 From Five Years Ago Is Worth Less Than $950
Impact · against what's priced in
The article offers no new catalysts for ABT, as the market has already priced in the Exact Sciences acquisition, the Libre Duo launch, and the nutrition spin-off. Current valuation reflects the stagnation in diabetes growth and conservative guidance, leaving the stock dependent on a yet-to-be-seen reacceleration in CGM volumes.
- ABT+0.00
Already priced in
- The price assumes
The $3 billion in 2026 sales contribution from the Exact Sciences acquisition





